Adherence to prevention and treatment therapeutics, as well as uptake and retention in care are critical challenges to sustained control of the HIV epidemic. Long-acting (LA) formulations designed to support long-term adherence and simplify treatment and prevention of HIV hold the promise of less burdensome therapeutic options, individual empowerment and wellbeing enhancement. Ensuring timely access to such game-changing innovations in low- and middle-income countries (LMICs) is key to minimise global health inequities. This satellite will provide an overview of LA products development and discuss opportunities and challenges for introduction of affordable LA solutions in HIV programmes in LMICs. The panel includes community representatives, industry and researchers focused on innovation in delivery methods, international implementing agencies, intergovernmental organisations and funders.

**AGENDA**

**Setting the scene: opportunities & challenges in long-acting landscape**

*Carmen Pérez Casas*

**Needs and potential for long-acting technologies**

- Community preferences, major concerns and ideal characteristics of long-acting products
  *Imelda Mahaka*

- Discussion on health care provider perspective and health systems implications
  *Beatriz Grinsztejn*

**Access: How do we go about it? Case Studies**

- Long-acting cabotegravir: Leading the way in long-acting HIV prevention therapy
  *Helen McDowell*

- Ensuring access to monoclonal antibodies
  *Shelly Malhotra*

**Moderated discussion** Facilitated by Rachel Baggaley

**Concluding remarks** Charles Gore